Xinbang Pharmaceutical: By End of 2024, Subsidiary Kekai Pharmacy Established Drug Retail Network Covering Existing and Major Partner Hospitals
Deep News
Jan 26
On January 26, Guizhou Xinbang Pharmaceutical Co.,Ltd. stated on an interactive platform in response to investor inquiries that by the end of the 2024 fiscal year, its subsidiary Kekai Pharmacy had successfully established a pharmaceutical retail network. This network comprehensively covers the company's existing hospitals and its major partner hospitals.
The company's coverage rate among Grade-A and above hospital clients across the province has surpassed 95%. Furthermore, its penetration rate within primary healthcare institutions throughout the province exceeds 45%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.